查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856968

全球神經退化性疾病市場：預測至 2032 年—按分子類型、適應症、藥物類別、給藥途徑、最終使用者和地區進行分析

Neurodegenerative Disease Market Forecasts to 2032 - Global Analysis By Molecule Type (Small-Molecule Drugs, Biologics and Cell & Gene Therapies), Indication, Drug Class, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球神經退化性疾病市場規模將達到 644 億美元，到 2032 年將達到 1,189 億美元，預測期內複合年成長率為 9.15%。

神經退化性疾病是指一組以神經細胞結構和功能逐漸喪失為特徵的疾病，最終導致神經細胞逐漸死亡。這些疾病會影響大腦和神經系統，損害認知、運動和感覺功能。常見的例子包括阿茲海默症、帕金森氏症、亨廷頓氏症和肌萎縮性側索硬化症（ALS）。其根本原因通常涉及異常蛋白質累積、基因突變、氧化壓力和粒線體功能障礙。由於神經細胞無法有效再生，這些疾病通常會發展為慢性病，並隨著時間的推移而惡化。由於其複雜性和缺乏有效治療方法，神經退化性疾病為醫學和社會帶來了重大挑戰。

生物標記和診斷技術的進步

研究人員正在開發體液和影像生物標記，以識別阿茲海默症、帕金森氏症和肌萎縮側索硬化症（ALS）的早期病理。人工智慧和機器學習的結合正在提高診斷準確性和疾病分層能力。製藥公司正在利用生物標記來最佳化試驗設計和治療標靶。伴隨診斷在精準神經病學研發管線中正變得越來越普遍。這些能力正在推動早期療育和個人化醫療領域的創新。

複雜疾病生物學與異質性

許多疾病的病因複雜，涉及遺傳、環境和發炎等多種因素。疾病進展在個體間差異很大，這使得臨床試驗終點和治療效果的評估變得複雜。臨床前研究因缺乏經過驗證的動物模型和轉化生物標記而受阻。監管機構要求提供在異質人群中療效和安全性的有力證據。這些挑戰持續阻礙藥物研發和平台規模化應用。

醫療保健支出和意識不斷提高

各國政府正在資助國家失智症戰略和老化相關研究計畫。旨在消除認知衰退和神經系統疾病污名化的宣傳活動正在進行中。醫院正在擴大記憶診所和神經復健中心，以滿足日益成長的需求。對數位醫療和遠端監測的投資正在支持長期護理和疾病管理。這些趨勢正在推動預防、診斷和治療創新領域的發展。

資源匱乏地區診斷途徑有限

許多地區缺乏訓練有素的神經科、影像基礎設施和分子檢測能力。農村和醫療服務不足的人面臨診斷延遲和專科診療機會有限的問題。 PET掃描、腦脊髓液檢測和基因檢測的費用和可近性仍然是新興市場的障礙。轉診途徑分散和公眾認知度低進一步損害了醫療品質。這些限制因素持續阻礙全球神經退化領域的公平性和治療效果。

新冠疫情的影響：

疫情擾亂了全球神經退化患者的臨床試驗、診斷和長期照護。封鎖和資源重新分配減緩了患者獲得治療和疾病監測的速度。然而，疫情後的復甦策略強調神經科照護的韌性和數位轉型。遠端醫療、遠距認知評估和數位生物標記已在老年族群中廣泛應用。疫情期間，民眾對神經系統健康的關注度有所提高，這影響了政策和研究重點。這些轉變正在加速對基礎設施、技術創新和以患者為中心的護理模式的投資。

預計在預測期內，阿茲海默症細分市場將成為最大的細分市場。

由於阿茲海默症領域將佔據最大的市場佔有率。製藥公司已推出針對澱粉樣蛋白和Tau蛋白病理的單株抗體和疾病修正治療。隨著人口老化，對早期檢測和風險分層的投資正在增加。與數位認知工具和體液生物標記的整合正在改善篩檢和監測。各國政府正在資助失智症研究和護理協調計畫。

預計細胞和基因治療領域在預測期內將達到最高的複合年成長率。

隨著治療方法在罕見和進行性神經退化性疾病中的應用日益廣泛，細胞和基因治療領域預計將在預測期內呈現最高的成長率。研發人員正利用病毒載體、幹細胞和基因編輯平台來恢復神經元功能並阻止疾病進展。監管機構正在為突破性療法提供快速審查和有條件核准。對生產規模化和遞送平台的投資正在提高治療的準備度和可負擔性。生物技術公司、醫院和支付方之間的夥伴關係正在支持治療的可及性和報銷模式。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的研究基礎設施、積極的監管參與以及人口老化趨勢。美國和加拿大擁有眾多領先的神經病學中心、臨床試驗網路和患者權益組織。美國食品藥物管理局（FDA）的快速通道和突破性療法認定等項目為創新和市場准入提供了支持。對生物標記開發和精準神經病學的投資正在推動平台擴張。領先的生物技術公司和學術機構的存在進一步鞏固了其市場領導地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這主要得益於醫療現代化、人口老化和政策改革的共同推動。中國、日本、印度和韓國等國家正在擴大都市區地區神經系統疾病診斷和治療的覆蓋範圍。政府支持的計畫正在推動失智症篩檢、公眾意識提升和基礎設施建設。區域生物技術公司正在推出針對特定族群適應症的細胞和基因療法。公共和私人醫療系統對經濟實惠且擴充性的解決方案的需求日益成長。這些趨勢正在推動整個神經退化性疾病生態系統的區域性成長。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球神經退化性疾病市場（依分子類型分類）

  • 小分子藥物
  • 生技藥品
  • 細胞和基因治療

6. 全球神經退化性疾病市場（依適應症分類）

  • 阿茲海默症
  • 帕金森氏症
  • 亨丁頓舞蹈症
  • 肌萎縮側索硬化症（ALS）
  • 多發性硬化症（MS）
  • 脊髓性肌肉萎縮症（SMA）
  • 其他跡象

7. 全球神經退化性疾病藥物市場

  • N-甲基-D-天門冬胺酸（NMDA）受體拮抗劑
  • 選擇性血清素再回收抑制劑（SSRIs）
  • 多巴胺促效劑和抑制劑
  • 膽鹼酯酶抑制劑
  • 單株抗體
  • 基因和RNA治療方法
  • 其他藥物類別

8. 全球神經退化性疾病市場（依給藥途徑分類）

  • 口服
  • 注射
  • 經皮
  • 鼻內

9. 全球神經退化性疾病市場（依最終用戶分類）

  • 醫院和診所
  • 研究和學術機構
  • 製藥和生物技術公司
  • 患者權益倡導組織
  • 其他最終用戶

10. 全球神經退化性疾病市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Biogen Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Eisai Co., Ltd.
  • Lundbeck A/S
  • Denali Therapeutics Inc.
Product Code: SMRC31832

According to Stratistics MRC, the Global Neurodegenerative Disease Market is accounted for $64.4 billion in 2025 and is expected to reach $118.9 billion by 2032 growing at a CAGR of 9.15% during the forecast period. Neurodegenerative disease refers to a group of disorders characterized by the progressive loss of structure or function of neurons, leading to their gradual death. These conditions affect the brain and nervous system, impairing cognitive, motor, and sensory functions. Common examples include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The underlying causes often involve abnormal protein accumulation, genetic mutations, oxidative stress, and mitochondrial dysfunction. As neurons cannot regenerate efficiently, these diseases are typically chronic and worsen over time. Neurodegenerative diseases pose significant medical and social challenges due to their complexity and lack of curative treatments.

Market Dynamics:

Driver:

Advances in biomarker & diagnostic technology

Researchers are developing fluid-based and imaging biomarkers to identify early-stage pathology in Alzheimer's, Parkinson's, and ALS. Integration with AI and machine learning is improving diagnostic accuracy and disease stratification. Pharmaceutical companies are using biomarkers to optimize trial design and therapeutic targeting. Companion diagnostics are gaining traction across precision neurology pipelines. These capabilities are propelling innovation in early intervention and personalized care.

Restraint:

Complex disease biology & heterogeneity

Many conditions involve multifactorial pathogenesis, including genetic, environmental, and inflammatory components. Disease progression varies widely across individuals, complicating trial endpoints and treatment response. Lack of validated animal models and translational biomarkers slows preclinical research. Regulatory bodies require robust evidence for efficacy and safety in heterogeneous populations. These challenges continue to hinder drug development and platform scalability.

Opportunity:

Rising healthcare spending & awareness

Governments are funding national dementia strategies and aging-related research programs. Public campaigns are improving awareness and reducing stigma around cognitive decline and neurological disorders. Hospitals are expanding memory clinics and neurorehabilitation centers to meet rising demand. Investment in digital health and remote monitoring is supporting long-term care and disease management. These trends are fostering growth across prevention, diagnosis, and therapeutic innovation.

Threat:

Limited diagnostic access in low-resource settings

Many regions lack trained neurologists, imaging infrastructure, and molecular testing capabilities. Rural and underserved populations face delays in diagnosis and limited access to specialized care. Cost and availability of PET scans, CSF assays, and genetic testing remain barriers in emerging markets. Fragmented referral pathways and low public awareness further degrade care quality. These constraints continue to hamper equity and outcomes across global neurodegenerative ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials, diagnostics, and long-term care for neurodegenerative patients worldwide. Lockdowns and resource reallocation delayed therapy access and disease monitoring. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in neurology care. Telemedicine, remote cognitive assessments, and digital biomarkers gained traction across aging populations. Public awareness of neurological health increased during the crisis, influencing policy and research priorities. These shifts are accelerating investment in infrastructure, innovation, and patient-centric care models.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period due to its high prevalence, diagnostic complexity, and therapeutic innovation. Pharmaceutical firms are launching monoclonal antibodies and disease-modifying therapies targeting amyloid and tau pathology. Investment in early detection and risk stratification is rising across aging populations. Integration with digital cognitive tools and fluid biomarkers is improving screening and monitoring. Governments are funding dementia research and care coordination programs.

The cell & gene therapies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell & gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across rare and progressive neurodegenerative conditions. Developers are using viral vectors, stem cells, and gene editing platforms to restore neuronal function and halt disease progression. Regulatory bodies are offering expedited review and conditional approvals for breakthrough therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and aging demographics. The United States and Canada host major neurology centers, clinical trial networks, and patient advocacy organizations. FDA programs such as Fast Track and Breakthrough Therapy Designation are supporting innovation and market entry. Investment in biomarker development and precision neurology is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, aging populations, and policy reform converge. Countries like China, Japan, India, and South Korea are scaling neurology diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting dementia screening, public awareness, and infrastructure development. Regional biotech firms are launching cell and gene therapies tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across neurodegenerative disease ecosystems.

Key players in the market

Some of the key players in Neurodegenerative Disease Market include AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Biogen Inc., Eli Lilly and Company, Johnson & Johnson, Eisai Co., Ltd., Lundbeck A/S and Denali Therapeutics Inc.

Key Developments:

In January 2025, AbbVie exercised its first opt-in under the collaboration with Capsida Biotherapeutics, securing rights to a gene therapy program for neurodegenerative diseases. The decision followed promising primate data showing effective delivery of AbbVie's therapeutic payload to the brain using Capsida's engineered AAV capsids, while minimizing off-target effects in the liver and dorsal root ganglia.

In September 2023, Amneal launched IPX203 in the U.S. following FDA approval for Parkinson's disease. The extended-release formulation demonstrated superior "on-time" versus immediate-release carbidopa-levodopa in Phase 3 trials, offering improved symptom control and dosing convenience for patients with advanced Parkinson's.

Molecule Types Covered:

  • Small-Molecule Drugs
  • Biologics
  • Cell & Gene Therapies

Indications Covered:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)
  • Spinal Muscular Atrophy (SMA)
  • Other Indications

Drug Classes Covered:

  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Dopamine Agonists & Inhibitors
  • Cholinesterase Inhibitors
  • Monoclonal Antibodies
  • Gene & RNA-Based Therapies
  • Other Drug Classes

Route of Administrations Covered:

  • Oral
  • Injectable
  • Transdermal
  • Intranasal

End Users Covered:

  • Hospitals & Clinics
  • Research & Academic Institutes
  • Pharmaceutical & Biotech Companies
  • Patient Advocacy Groups
  • Other End-Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurodegenerative Disease Market, By Molecule Type

  • 5.1 Introduction
  • 5.2 Small-Molecule Drugs
  • 5.3 Biologics
  • 5.4 Cell & Gene Therapies

6 Global Neurodegenerative Disease Market, By Indication

  • 6.1 Introduction
  • 6.2 Alzheimer's Disease
  • 6.3 Parkinson's Disease
  • 6.4 Huntington's Disease
  • 6.5 Amyotrophic Lateral Sclerosis (ALS)
  • 6.6 Multiple Sclerosis (MS)
  • 6.7 Spinal Muscular Atrophy (SMA)
  • 6.8 Other Indications

7 Global Neurodegenerative Disease Market, By Drug Class

  • 7.1 Introduction
  • 7.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • 7.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
  • 7.4 Dopamine Agonists & Inhibitors
  • 7.5 Cholinesterase Inhibitors
  • 7.6 Monoclonal Antibodies
  • 7.7 Gene & RNA-Based Therapies
  • 7.8 Other Drug Classes

8 Global Neurodegenerative Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Injectable
  • 8.4 Transdermal
  • 8.5 Intranasal

9 Global Neurodegenerative Disease Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research & Academic Institutes
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Patient Advocacy Groups
  • 9.6 Other End-Users

10 Global Neurodegenerative Disease Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Amneal Pharmaceuticals LLC
  • 12.3 Boehringer Ingelheim GmbH
  • 12.4 F. Hoffmann-La Roche Ltd.
  • 12.5 Merck & Co., Inc.
  • 12.6 Novartis AG
  • 12.7 Pfizer Inc.
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 UCB S.A.
  • 12.10 Biogen Inc.
  • 12.11 Eli Lilly and Company
  • 12.12 Johnson & Johnson
  • 12.13 Eisai Co., Ltd.
  • 12.14 Lundbeck A/S
  • 12.15 Denali Therapeutics Inc.

List of Tables

  • Table 1 Global Neurodegenerative Disease Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Neurodegenerative Disease Market Outlook, By Molecule Type (2024-2032) ($MN)
  • Table 3 Global Neurodegenerative Disease Market Outlook, By Small-Molecule Drugs (2024-2032) ($MN)
  • Table 4 Global Neurodegenerative Disease Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 5 Global Neurodegenerative Disease Market Outlook, By Cell & Gene Therapies (2024-2032) ($MN)
  • Table 6 Global Neurodegenerative Disease Market Outlook, By Indication (2024-2032) ($MN)
  • Table 7 Global Neurodegenerative Disease Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 8 Global Neurodegenerative Disease Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 9 Global Neurodegenerative Disease Market Outlook, By Huntington's Disease (2024-2032) ($MN)
  • Table 10 Global Neurodegenerative Disease Market Outlook, By Amyotrophic Lateral Sclerosis (ALS) (2024-2032) ($MN)
  • Table 11 Global Neurodegenerative Disease Market Outlook, By Multiple Sclerosis (MS) (2024-2032) ($MN)
  • Table 12 Global Neurodegenerative Disease Market Outlook, By Spinal Muscular Atrophy (SMA) (2024-2032) ($MN)
  • Table 13 Global Neurodegenerative Disease Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 14 Global Neurodegenerative Disease Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 15 Global Neurodegenerative Disease Market Outlook, By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (2024-2032) ($MN)
  • Table 16 Global Neurodegenerative Disease Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2024-2032) ($MN)
  • Table 17 Global Neurodegenerative Disease Market Outlook, By Dopamine Agonists & Inhibitors (2024-2032) ($MN)
  • Table 18 Global Neurodegenerative Disease Market Outlook, By Cholinesterase Inhibitors (2024-2032) ($MN)
  • Table 19 Global Neurodegenerative Disease Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 20 Global Neurodegenerative Disease Market Outlook, By Gene & RNA-Based Therapies (2024-2032) ($MN)
  • Table 21 Global Neurodegenerative Disease Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 22 Global Neurodegenerative Disease Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 23 Global Neurodegenerative Disease Market Outlook, By Oral (2024-2032) ($MN)
  • Table 24 Global Neurodegenerative Disease Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 25 Global Neurodegenerative Disease Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 26 Global Neurodegenerative Disease Market Outlook, By Intranasal (2024-2032) ($MN)
  • Table 27 Global Neurodegenerative Disease Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Neurodegenerative Disease Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 29 Global Neurodegenerative Disease Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 30 Global Neurodegenerative Disease Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 31 Global Neurodegenerative Disease Market Outlook, By Patient Advocacy Groups (2024-2032) ($MN)
  • Table 32 Global Neurodegenerative Disease Market Outlook, By Other End-Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.